You are here

Eli Lilly

A new market beckons for Alzheimer’s blood tests

A new market beckons for Alzheimer’s blood tests

EP Vantage

Alzheimer's disease

Flag link:

Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab

Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab

Reuters

Flag link:

Eli Lilly axes 163 Dermira staffers, shutters Menlo Park site as it closes in around Dupixent rival lebrikizumab

Eli Lilly axes 163 Dermira staffers, shutters Menlo Park site as it closes in around Dupixent rival lebrikizumab

Endpoints

Flag link:

Lilly, Arch join Deerfield in backing new gene therapy biotech Jaguar

Lilly, Arch join Deerfield in backing new gene therapy biotech Jaguar

BioPharma Dive

Jaguar Gene Therapy

Arch Venture Partners

Flag link:

With variants spreading, Eli Lilly cuts solo COVID-19 antibody out of its U.S. supply deal

With variants spreading, Eli Lilly cuts solo COVID-19 antibody out of its U.S. supply deal

Fierce Pharma

bamlanivimab-etesevimab

Flag link:

5 takeaways from AACR, one of the year's top meetings on cancer drugs

5 takeaways from AACR, one of the year's top meetings on cancer drugs

BioPharma Dive

Bristol Myers Squibb

Flag link:

Pharma's pandemic reputation gains score a 'most-improved' medal in annual ranking

Pharma's pandemic reputation gains score a 'most-improved' medal in annual ranking

Fierce Pharma

pharma industry

Bristol Myers Squibb

Flag link:

Lilly gene-targeted drug shows potential for use across cancers

Lilly gene-targeted drug shows potential for use across cancers

BioPharma Dive

clinical trials

Flag link:

Lilly claims promising finding in failed study of COVID-19 drug

Lilly claims promising finding in failed study of COVID-19 drug

BioPharma Dive

Flag link:

Series of JAK inhibitor delays may signal an upcoming FDA adcomm

Series of JAK inhibitor delays may signal an upcoming FDA adcomm

Endpoints

Flag link:

FDA pushes eczema decision for Eli Lilly's Olumiant, Pfizer's abrocitinib back 3 months — raising more questions for the JAK class

FDA pushes eczema decision for Eli Lilly's Olumiant, Pfizer's abrocitinib back 3 months — raising more questions for the JAK class

Endpoints

Flag link:

Eli Lilly, GlaxoSmithKline-Vir release positive but difficult-to-interpret combo antibody data

Eli Lilly, GlaxoSmithKline-Vir release positive but difficult-to-interpret combo antibody data

Endpoints

Vir Biotechnology

clinical trials

Flag link:

Ex-lobbyist sues Eli Lilly alleging sexual discrimination, harassment

Ex-lobbyist sues Eli Lilly alleging sexual discrimination, harassment

Reuters

gender discrimination

Flag link:

FDA Advisory Committee Raises Objections to Pfizer and Eli Lilly’s Tanezumab

FDA Advisory Committee Raises Objections to Pfizer and Eli Lilly’s Tanezumab

BioSpace

advisory panels

Flag link:

Will Another Alzheimer's Disease Drug Bite the Dust After Lilly's Latest Results?

Will Another Alzheimer's Disease Drug Bite the Dust After Lilly's Latest Results?

Motley Fool

Alzheimer's disease

Flag link:

Pfizer has run 41 trials over 15 years for tanezumab. As adcomm nears, the FDA remains unimpressed — and more than a little worried

Pfizer has run 41 trials over 15 years for tanezumab. As adcomm nears, the FDA remains unimpressed — and more than a little worried

Endpoints

advisory panels

Flag link:

Eli Lilly’s Covid-19 drug bamlanivimab is no longer distributed in 3 states because of a variant, Woodcock says

Eli Lilly’s Covid-19 drug bamlanivimab is no longer distributed in 3 states because of a variant, Woodcock says

Endpoints

COVID-19 variants

Flag link:

Court win for Eli Lilly halts HHS’s drug discount rule

Court win for Eli Lilly halts HHS’s drug discount rule

Endpoints

Flag link:

4 Pharma Stocks That Could Be Losers With the $1.9 Trillion Stimulus Package

4 Pharma Stocks That Could Be Losers With the $1.9 Trillion Stimulus Package

Motley Fool

Jazz Pharmaceuticals

Flag link:

Eli Lilly, Novartis back a biotech startup boasting 'best of both worlds' protein degraders

Eli Lilly, Novartis back a biotech startup boasting 'best of both worlds' protein degraders

Endpoints

protein degradation

Flag link:

Pages